Holen Sie sich die Stockscreener-App
1.31
0.00%
0.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.31
Offen:
$1.31
24-Stunden-Volumen:
1.10M
Relative Volume:
0.46
Marktkapitalisierung:
$547.40M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.6375
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+6.50%
1M Leistung:
+9.17%
6M Leistung:
+18.02%
1J Leistung:
+76.72%
1-Tages-Spanne:
$1.28
$1.35
1-Wochen-Bereich:
$1.17
$1.385
52-Wochen-Spanne:
$0.2836
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.31 | 547.40M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
How rising interest rates impact Lexicon Pharmaceuticals Inc. stock2025 Analyst Calls & Free Daily Entry Point Trade Alerts - mfd.ru
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
Sentiment Recap: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteriaTrade Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Lexicon Pharmaceuticals completes $100 million stock offering By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals completes $100 million stock offering - Investing.com
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon Pharmaceuticals Completes Public Offering of Common Stock and Concurrent Private Placement - Quiver Quantitative
Lexicon raises about $94.6M to fund drug work and operations - Stock Titan
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Insider Buying: Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Acquires 1,538,462 Shares of Stock - MarketBeat
Market Review: How does Lexicon Pharmaceuticals Inc compare to its peersWeekly Market Outlook & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Lexicon Pharmaceuticals Bolsters Capital Through Equity Financing - The Globe and Mail
Lexicon Pharmaceuticals Signs Multiple Material Agreements - TradingView
FOMO Trade: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Momentum Check & Capital Protection Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals Initiates Stock Offering to Drive R&D Growth - StocksToTrade
Lexicon Pharmaceuticals Stock Offering: Strategic Move to Boost R&D - timothysykes.com
Pullback Watch: Can Lexicon Pharmaceuticals Inc reach all time highs this yearWeekly Trading Summary & Technical Pattern Alert System - baoquankhu1.vn
Lexicon Pharmaceuticals Announces Key Stock Offering amid Strategic Funding Efforts - StocksToTrade
Lexicon Pharmaceuticals prices public offering at $1.30 per share By Investing.com - Investing.com Nigeria
Lexicon Pharmaceuticals launches public offering of common stock By Investing.com - Investing.com Australia
Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones - Finviz
Lexicon Pharmaceuticals stock tumbles on public offering pricing By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals (LXRX) Engages Jefferies and Piper Sandl - GuruFocus
Lexicon Pharmaceuticals stock tumbles on public offering pricing - Investing.com India
Lexicon Pharmaceuticals (LXRX) Raises $41.6M Through Public Offe - GuruFocus
Lexicon Pharmaceuticals prices public offering at $1.30 per share - Investing.com
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement - The Manila Times
Lexicon announces pricing of approximately $94.6 million public offering at $1.30 per share - marketscreener.com
Drug developer Lexicon raises $94.6M to fund pipeline and operations - stocktitan.net
Lexicon Pharmaceuticals (LXRX) Initiates Public Stock Offering - GuruFocus
Lexicon Pharmaceuticals (LXRX) Launches Public Offering, Shares Dip - GuruFocus
Lexicon Pharmaceuticals launches public offering of common stock - Investing.com
Lexicon Announces Proposed Public Offering of Common Stock - The Manila Times
Lexicon (NASDAQ: LXRX) plans stock sale, highlights late-stage pipeline - stocktitan.net
Lexicon plans stock sale to fund drug candidate research, operations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 8.5%Should You Sell? - MarketBeat
Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - ChartMill
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Swain Judith L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
85,174 |
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):